Literature DB >> 26557170

Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.

Annio Posar1, Raffaella Faggioli2, Paola Visconti3.   

Abstract

The phenotype of cyclin-dependent kinase-like 5 (CDKL5) syndrome includes Rett syndrome variant with early onset seizures, early onset epileptic encephalopathy; and severe developmental delay. Autistic features have often been reported in literature, but detailed reports of the behavior of these individuals are lacking. We describe the clinical picture of a girl aged 15 years 9 months affected by CDKL5 syndrome, with special attention to the neurobehavioral phenotype. The evaluation showed, apart from a profound intellectual disability, the presence of atypical features of behavior, mainly in relating to people, in imitation, and in verbal and nonverbal communication, thus justifying the diagnosis of comorbid autism spectrum disorder. A formal assessment of the behavior, through appropriate tools, is necessary to choose the most appropriate rehabilitative intervention and to characterize in more detail the CDKL5 syndrome phenotype. We propose a testing protocol for the neurobehavioral assessment of these patients.

Entities:  

Keywords:  Autism; cyclin-dependent kinase-like 5; intellectual disability; neurobehavioral phenotype

Year:  2015        PMID: 26557170      PMCID: PMC4611898          DOI: 10.4103/1817-1745.165685

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


Introduction

Mutations of cyclin-dependent kinase-like 5 (CDKL5) gene, located on the short arm of X chromosome, have been found in individuals with: Rett syndrome variant with early onset seizures, described by Hanefeld in 1985; early onset epileptic encephalopathy; severe developmental delay.[123] Within the phenotypic spectrum of CDKL5 gene alterations, male cases tend to be more impaired.[34] Autistic features (stereotypies, eye contact deficit, and reduced social interaction) have been reported by many authors,[12345678910] but detailed reports specifically addressing the neurobehavioral phenotype are lacking. We describe a girl affected by CDKL5 syndrome, with special attention to the neurobehavioral phenotype.

Case Report

The patient's family history was negative for neuropsychiatric disorders. The mother had one spontaneous abortion. Pre-, peri-, and neonatal periods were normal. Weight growth was mildly impaired (3rd to 10th percentile) while height growth was normal. A mild, global delay of psychomotor development was present from the beginning, but, after the onset of epilepsy at the age of 7 months, a regression has been detected and over time poor participation and interest in the environment became evident. The girl started to walk without support at 2 years of age and never developed speech. She had drug-resistant seizures occurring more than once a day: generalized tonic-clonic, myoclonic, and spasms in flexion. The following genetic and neurometabolic investigations were negative: CGH-array, molecular analysis of SCN1A and MECP2 genes, sialotransferrin isoelectric focusing, dosage of ammonia, lactic acid, plasmatic amino acids, urinary organic acids, and acilcarnitine. Molecular analysis of CDKL5 gene revealed a nucleotide deletion mutation in the exon 12 (c. 1853-1854delC), absent in the parents. Brain magnetic resonance imaging was normal. At our observation (15 years 9 months), she was on phenobarbital and levetiracetam: seizures persisted and were frequent. Neurological examination showed: absent speech, bilateral alternating strabismus, hypotonia, bruxism, wide-based “robot-like” gait, joint laxity, and muscle hypotrophy. Electroencephalogram showed diffuse alterations of electrogenesis and frequent, diffuse paroxysmal abnormalities in both hemispheres prevailing in the fronto-temporal regions.

Neurobehavioral assessment

The administration of a standardized test to measure the intelligence quotient was impossible, mainly due to lack of cooperation and understanding of the verbal message. Vineland scales, designed to assess adaptive behavior, showed a profound impairment, with scores corresponding to an age <18 months in all four domains explored: communication; daily living skills; socialization; and motor skills. According to Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) criteria,[11] the degree of intellectual disability has been judged as profound. International Scoring System (ISS)[12] is a tool aimed at evaluating the features usually associated with the Rett syndrome phenotypes (classic or variant). ISS includes 20 items that assess the following areas: growth and development; musculo-skeletal system; movement; cortical functioning; brainstem and autonomic functioning. Item scores range from 0 (no abnormality) to 2 (severe abnormality), with an intermediate possibility = 1 (mild severity). The ISS score of our patient was 15, compatible with a level of mild-moderate severity. Unstructured observation of behavior showed: inconstant eye contact; absence of joint attention; absence of both declarative and imperative pointing; very poor social initiative, despite the acceptance of the interaction initiated by others; inadequate response to verbal call; absent speech, uttering of not finalized vocalizations; lack of purposeful use of the hands; stereotypies such as hand-mouthing; breathing irregularities such as apneas alternating with hyperventilation; very restricted and repetitive interests and activities, such as opening and closing the doors iteratively. Childhood Autism Rating Scale, Second Edition – Standard Version (CARS2-ST) is a 15-item rating scale aimed at identifying children with autism spectrum disorder and evaluating symptom severity by attributing to each item a score from a minimum = 1 (normotypic) to a maximum = 4 (the most atypical). CARS2-ST showed a total score = 36/60, higher than the cut-off (= 35) for the presence of severe signs of autism spectrum disorder. The most impaired CARS2-ST items (such as those with a score of at least 3) were: relating to people; imitation; verbal communication; and nonverbal communication [Table 1].
Table 1

Profile of the scores (from 1 = normotypic to 4 = the most atypical) of the 15 categories of signs included in the Childhood Autism Rating Scale, Second Edition – Standard Version, when our patient was 15 years and 9 months old

Profile of the scores (from 1 = normotypic to 4 = the most atypical) of the 15 categories of signs included in the Childhood Autism Rating Scale, Second Edition – Standard Version, when our patient was 15 years and 9 months old In conclusion, the data from the neurobehavioral assessment showed a profound intellectual disability and a comorbid autism spectrum disorder according to DSM-5 criteria.[11]

Discussion

Literature data suggest some heterogeneity of the neurobehavioral phenotype in individuals with CDKL5 gene alterations, but detailed reports regarding this topic are lacking. In fact, there are other aspects of the phenotype of this syndrome, particularly the early onset severe epilepsy with impairment of developmental skills, which have so far been more frequently described.[13] In our view, there is a risk of overshadowing the clinical features of the CDKL5 syndrome related to the behavior, thus losing an opportunity to find a correlation between a well-defined genetic disorder and the associated phenotype, as well as suggestions for tailored treatment strategies. In the description of our case with CDKL5 syndrome, we specifically intended to focus on the characteristics of behavior. The neurodevelopment of our patient was not only very poor but also atypical. In fact, there were significant pathological features of behavior, mainly in relating to people, in imitation, and in verbal and nonverbal communication, thus justifying the diagnosis of autism spectrum disorder comorbid with the intellectual disability. These features should be considered for a detailed clinical characterization as well as for a better development of rehabilitation programs for patients. With this aim, we emphasize the usefulness of a systematic study of cases with CDKL5 gene alterations, through a formal evaluation, in order to assess behavior phenotype at onset and during the follow-up, and monitoring intervention effects. We consider it necessary to set up a neurobehavioral protocol, involving the use of at least the following tools: CARS2-ST, Vineland scales, ISS and, whenever possible, a scale of intelligence (Wechsler or Leiter, as appropriate), even if this is often unfeasible due to the severity of intellectual disability. Indeed, the Autism Diagnostic Observation Schedule, Second Edition would be the most suitable tool for a formal autism diagnosis, but most of the times it cannot be used because it requires the presence of motor, in particular manual, skills which are very often lacking in these patients.

Conclusion

CDKL5 syndrome constitutes a well-studied genetic nosographic entity. In our opinion, it requires an in-depth analysis of the phenotype through a systematic study of the behavior, which should be carried out using reliable assessment tools in order to acquire data and suggestions to set up rehabilitation programs and to monitor outcomes.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  12 in total

1.  Guidelines for reporting clinical features in cases with MECP2 mutations.

Authors:  A M Kerr; Y Nomura; D Armstrong; M Anvret; P V Belichenko; S Budden; H Cass; J Christodoulou; A Clarke; C Ellaway; M d'Esposito; U Francke; M Hulten; P Julu; H Leonard; S Naidu; C Schanen; T Webb; I W Engerstrom; Y Yamashita; M Segawa
Journal:  Brain Dev       Date:  2001-07       Impact factor: 1.961

2.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.

Authors:  Stephanie Fehr; Meredith Wilson; Jenny Downs; Simon Williams; Alessandra Murgia; Stefano Sartori; Marilena Vecchi; Gladys Ho; Roberta Polli; Stavroula Psoni; Xinhua Bao; Nick de Klerk; Helen Leonard; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-08-08       Impact factor: 4.246

3.  Early onset seizures and Rett-like features associated with mutations in CDKL5.

Authors:  Julie C Evans; Hayley L Archer; James P Colley; Kirstine Ravn; Jytte Bieber Nielsen; Alison Kerr; Elizabeth Williams; John Christodoulou; Jozef Gécz; Philip E Jardine; Michael J Wright; Daniela T Pilz; Lazarus Lazarou; David N Cooper; Julian R Sampson; Rachel Butler; Sharon D Whatley; Angus J Clarke
Journal:  Eur J Hum Genet       Date:  2005-10       Impact factor: 4.246

Review 4.  Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.

Authors:  Renzo Guerrini; Elena Parrini
Journal:  Epilepsia       Date:  2012-09-21       Impact factor: 5.864

5.  Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.

Authors:  Linda S Weaving; John Christodoulou; Sarah L Williamson; Kathie L Friend; Olivia L D McKenzie; Hayley Archer; Julie Evans; Angus Clarke; Gregory J Pelka; Patrick P L Tam; Catherine Watson; Hooshang Lahooti; Carolyn J Ellaway; Bruce Bennetts; Helen Leonard; Jozef Gécz
Journal:  Am J Hum Genet       Date:  2004-10-18       Impact factor: 11.025

6.  Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.

Authors:  Jiong Tao; Hilde Van Esch; M Hagedorn-Greiwe; Kirsten Hoffmann; Bettina Moser; Martine Raynaud; Jürgen Sperner; Jean-Pierre Fryns; Eberhard Schwinger; Jozef Gécz; Hans-Hilger Ropers; Vera M Kalscheuer
Journal:  Am J Hum Genet       Date:  2004-12       Impact factor: 11.025

7.  CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life.

Authors:  Federico Melani; Davide Mei; Tiziana Pisano; Salvatore Savasta; Emilio Franzoni; Anna Rita Ferrari; Carla Marini; Renzo Guerrini
Journal:  Dev Med Child Neurol       Date:  2011-02-11       Impact factor: 5.449

8.  CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.

Authors:  H L Archer; J Evans; S Edwards; J Colley; R Newbury-Ecob; F O'Callaghan; M Huyton; M O'Regan; J Tolmie; J Sampson; A Clarke; J Osborne
Journal:  J Med Genet       Date:  2006-04-12       Impact factor: 6.318

9.  Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria.

Authors:  R Artuso; M A Mencarelli; R Polli; S Sartori; F Ariani; M Pollazzon; A Marozza; M R Cilio; N Specchio; F Vigevano; M Vecchi; C Boniver; B Dalla Bernardina; A Parmeggiani; S Buoni; G Hayek; F Mari; A Renieri; A Murgia
Journal:  Brain Dev       Date:  2009-04-10       Impact factor: 1.961

10.  Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.

Authors:  Ying Zhao; Xiaoying Zhang; Xinhua Bao; Qingping Zhang; Jingjing Zhang; Guangna Cao; Jie Zhang; Jiarui Li; Liping Wei; Hong Pan; Xiru Wu
Journal:  BMC Med Genet       Date:  2014-02-25       Impact factor: 2.103

View more
  4 in total

Review 1.  Autism, epilepsy, and synaptopathies: a not rare association.

Authors:  Roberto Keller; Roberta Basta; Luana Salerno; Maurizio Elia
Journal:  Neurol Sci       Date:  2017-04-28       Impact factor: 3.307

2.  Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers.

Authors:  Ethan Schroeder; Li Yuan; Eunju Seong; Cheryl Ligon; Nicholas DeKorver; C B Gurumurthy; Jyothi Arikkath
Journal:  Mol Neurobiol       Date:  2018-10-04       Impact factor: 5.590

3.  NGL-1/LRRC4C-Mutant Mice Display Hyperactivity and Anxiolytic-Like Behavior Associated With Widespread Suppression of Neuronal Activity.

Authors:  Yeonsoo Choi; Haram Park; Suwon Kang; Hwajin Jung; Hanseul Kweon; Seoyeong Kim; Ilsong Choi; Soo Yeon Lee; Ye-Eun Choi; Seung-Hee Lee; Eunjoon Kim
Journal:  Front Mol Neurosci       Date:  2019-10-11       Impact factor: 5.639

4.  CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.

Authors:  Zhenfu Jiang; Tongtong Gong; Hong Wei
Journal:  FEBS Open Bio       Date:  2020-01-21       Impact factor: 2.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.